Here is a possibility as well. I mentioned this in an earlier post. The news today might help with the IPO in a roundabout way. The IND gets submitted in China, the trials gets pushed quickly and phase 1 and 2 get rapidly completed.

News of this helps the advancement now of the IPO listing as well, because the 1.5 billion deal is more tangible, especially because of the testing results being successful, backing in China is a full go now.

Generex / NGIO obtain full rights outside of China and with China paying for everything in China, things speed up and with Bintai and the 1.billion dollar deal still going on and Malaysia now investing oil money to help with vaccine push, that helps on that front.

Then with everything going on in India, it makes the IPO for NGIO seem more viable now because it's worth at least 500 million already, China is now truly involved and things are starting to come together that could lead to bigger things overall, especially outside the US where you are looking at billions and billions.